Q-linea ASTar 系统直接对阳性血培养革兰阴性杆菌进行快速表型药敏检测的前瞻性评估
该前瞻性研究在真实条件下评估 Q-linea ASTar 系统直接从阳性血培养进行快速药敏试验,并与 VITEK 2 及微量肉汤稀释法比较。共测试 78 株菌(51 株前瞻性、27 株存档),ASTar 覆盖 94% 的菌种,分类一致率 95.6%、基本一致率 90.7%,平均出报告时间 28 小时 49 分钟,显著短于标准流程的 44 小时 18 分钟。
要点
- ASTar 直接自阳性血培养进行药敏试验,分类一致率与标准流程相似。
- 低耐药环境下能从 ASTar 获益的患者比例有限,且提前调整治疗对预后影响尚不明确。
核心结论
- ASTar 提供了可靠的药敏结果并显著缩短了获得药敏报告的时间。
- 在低耐药环境下能从 ASTar 获益的患者比例有限,且采血后 29 小时更改治疗是否显著影响预后目前尚不清楚。
研究设计与样本
- 前瞻性研究,在真实条件下评估 ASTar 系统,并与标准流程(短期培养后 VITEK 2)比较,两者均以微量肉汤稀释法为参考。
- 共测试 78 株细菌,包括 51 株前瞻性阳性血培养菌株和 27 株存档的多重耐药革兰阴性菌。
主要发现
- ASTar 覆盖了所遇菌种的 94%。
- 分类一致率为 95.6%,基本一致率为 90.7%。
- ASTar 产生 2.4% 次要错误、2.0% 重大错误和 2.4% 极重大错误,分类一致率与标准流程相似。
- 从血培养采样到主治医生获得药敏报告的平均时间:ASTar 为 28 小时 49 分钟,标准流程为 44 小时 18 分钟。
- ASTar 正确识别了所有需要升级抗菌治疗的患者以及 75% 符合降级治疗条件的患者。
临床怎么用
- ASTar 可用于直接自阳性血培养快速获得革兰阴性杆菌的药敏结果,缩短报告时间。
- 在低耐药环境中,需结合本地流行病学评估 ASTar 的实际获益人群。
局限性
- 在低耐药环境下能从 ASTar 获益的患者比例有限。
- 采血后 29 小时更改治疗是否显著影响患者预后目前尚不清楚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adequate and timely antibiotic therapy is crucial for the treatment of sepsis. Innovative systems, like the Q-linea ASTar, have been developed to perform rapid antimicrobial susceptibility testing (AST) directly from positive blood cultures (BCs). We conducted a prospective study to evaluate ASTar under real-life conditions with a focus on time-to-result and impact on antimicrobial therapy. Over 2 months, all positive BCs that showed Gram-negative rods upon microscopy were tested with the ASTar and our standard procedure (VITEK 2 from short-term culture). Additionally, we included multidrug-resistant Gram-negative bacteria from our archive. Both methods were compared to broth microdilution. In total, 78 bacterial strains (51 prospective and 27 archived) were tested. ASTar covered 94% of the species encountered. The categorical and essential agreement was 95.6% and 90.7%, respectively. ASTar caused 2.4% minor, 2.0% major, and 2.4% very major errors. The categorical agreement was similar to standard procedure. The average time between BC sampling and the availability of the antibiogram for the attending physician was 28 h 49 min for ASTar and 44 h 18 min for standard procedure. ASTar correctly identified all patients who required an escalation of antimicrobial therapy and 75% of those who were eligible for de-escalation. In conclusion, ASTar provided reliable AST results and significantly shortened the time to obtain an antibiogram. However, the percentage of patients that will profit from ASTar in a low-resistance setting is limited, and it is currently unclear if a change of therapy 29 h after BC sampling will have a significant impact on the patient's prognosis.
引用
- Esse J, Träger J, Valenza G, et al. Rapid phenotypic antimicrobial susceptibility testing of Gram-negative rods directly from positive blood cultures using the novel Q-linea ASTar system. J Clin Microbiol. 2023. PMID: 37819072. doi:10.1128/jcm.00549-23
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。